RudaCure Co., Ltd. develops treatments for diseases with sensory based disorders and high unmet needs. Pipeline is divided into treatments via Rac1 inhibition and TRPV1 antagonism. Programs targeting Rac1 include treatments for Dry Eye, Corneal Ulcers, Atopic Dermatitis, Psoriasis, Melanoma and Wet-AMD. Programs targeting TRPV1 include treatments for chronic pain indications such as osteoarthritis pain and, chemotherapy induced peripheral neuropathy (CIPN) and CRPS.

Rudacure Co., Ltd. also provides animal models for pain and eye diseases, electrophysiological research, and drug toxicity and efficacy assessment services.